Princeton University
Jan 08, 2019
Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod
The oral depression drug of Sage Therapeutics meets phase 3 efficacy A phase 3 trial of oral treatment of Sage Therapeutics for postpartum depression (PPD) has hit its primary endpoint. The drug, SAGE-217, showed significant improvements on a depression score and saw no fainting cases. SAGE-217 is an a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
